Beijing Hotgen Biotech Hits Day Low at CNY 124 Amid Price Pressure

Beijing Hotgen Biotech Co., Ltd. experienced significant volatility on July 17, 2026, with the stock declining by 11.01% and reaching an intraday low of CNY 124.00. This performance starkly contrasts with the China Shanghai Composite, which fell by 3.05% on the same day. Over the past week, Beijing Hotgen has shown a modest increase of 2.37%, but its longer-term performance reveals more concerning trends. The stock has dropped 36.38% over the past year, while the Shanghai Composite has gained 7.03%. Year-to-date, the stock is down 21.45%, compared to a decline of 5.16% for the broader index. Financial metrics indicate challenges for the company, with net sales decreasing by 4.41% and a net profit of CNY -75.78 million, reflecting a decline of 58.81%. The company has reported negative results for the last 12 consecutive quarters, raising concerns about its financial health. Additionally, the return on equity stands at -11.89%, and the stock is trading at a price-to-book ratio of 3.00, suggesting potential overvaluation in the current market environment.